Netanel Derovan - Oramed Pharmaceuticals Chief Secretary
| ORMP Stock | USD 2.37 0.02 0.85% |
Executive
Netanel Derovan is Chief Secretary of Oramed Pharmaceuticals
| Age | 48 |
| Address | 1185 Avenue of the Americas, New York, NY, United States, 10036 |
| Phone | 844 967 2633 |
| Web | https://www.oramed.com |
Oramed Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0412) % which means that it has lost $0.0412 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0289 %, meaning that it created $0.0289 on every $100 dollars invested by stockholders. Oramed Pharmaceuticals' management efficiency ratios could be used to measure how well Oramed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/28/2024, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.25. At this time, Oramed Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 11/28/2024, Liabilities And Stockholders Equity is likely to grow to about 195.2 M, while Non Current Liabilities Total is likely to drop slightly above 4.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gayle Gironda | Inozyme Pharma | N/A | |
| MD MBA | Ocean Biomedical | 59 | |
| James MD | Corvus Pharmaceuticals | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
| Jason JD | Immunitybio | 41 | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Ben JD | Immix Biopharma | N/A | |
| Desiree Gendron | Lexicon Pharmaceuticals | N/A | |
| Joseph Reilly | Ardelyx | 51 | |
| Michael Howell | Zura Bio Limited | 47 | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| David Marks | Immix Biopharma | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| Dixon Terry | Lexicon Pharmaceuticals | N/A | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Yael Fellous | Protalix Biotherapeutics | N/A | |
| Joerg Heyer | Palisade Bio | N/A | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Elizabeth Esq | Ardelyx | 60 | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
Management Performance
| Return On Equity | 0.0289 | ||||
| Return On Asset | -0.0412 |
Oramed Pharmaceuticals Leadership Team
Elected by the shareholders, the Oramed Pharmaceuticals' board of directors comprises two types of representatives: Oramed Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oramed. The board's role is to monitor Oramed Pharmaceuticals' management team and ensure that shareholders' interests are well served. Oramed Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oramed Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Rabinowitz, Chief Officer | ||
| David CPA, CFO Treasurer | ||
| Nadav Esq, CEO President | ||
| Miriam Kidron, Chief Scientific Officer and Director | ||
| Avraham Gabay, Treasurer CFO | ||
| Roy MD, Chief Board | ||
| Joshua Hexter, COO and VP of Bus. Devel. | ||
| Netanel Derovan, Chief Secretary |
Oramed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oramed Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0289 | ||||
| Return On Asset | -0.0412 | ||||
| Current Valuation | (47.14 M) | ||||
| Shares Outstanding | 40.77 M | ||||
| Shares Owned By Insiders | 10.62 % | ||||
| Shares Owned By Institutions | 17.32 % | ||||
| Number Of Shares Shorted | 313.9 K | ||||
| Price To Earning | (11.22) X | ||||
| Price To Book | 0.61 X | ||||
| Price To Sales | 141.54 X |
Pair Trading with Oramed Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oramed Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oramed Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Oramed Stock
| 0.61 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.54 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.42 | GILD | Gilead Sciences | PairCorr |
| 0.42 | PMVP | Pmv Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Oramed Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oramed Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oramed Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oramed Pharmaceuticals to buy it.
The correlation of Oramed Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oramed Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oramed Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oramed Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.